Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
COCP similar filings
- 21 Dec 23 Termination of a Material Definitive Agreement
- 6 Dec 23 Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
- 4 Dec 23 Regulation FD Disclosure
- 29 Nov 23 Regulation FD Disclosure
- 13 Nov 23 Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
- 31 Oct 23 Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
- 16 Aug 23 Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Filing view
External links
Exhibit 99.1